Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthorStephenLurieMD, PhDIndividualAuthor
Copyright 1999 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: The study by Dr Steinhubl and
colleagues1 concludes that TTP is due to
ticlopidine after coronary stenting. However, the authors have not considered
appropriate criteria for causality. The first criterion is the magnitude and
consistency of the association. Despite an estimated 1.4 million annual prescriptions
for ticlopidine and 7 previous prospective studies of ticlopidine after stenting
(n = 2978), there are insufficient data to estimate a measure of association,
let alone find consistency.
McCullough PA, Marks KR. Ticlopidine and TTP After Coronary Stenting. JAMA. 1999;282(18):1717-1719. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-18-jbk1110